Bone grafts versus synthetic bone substitutes in the treatment of benign bone tumors
Published Online: May 14, 2022
Page range: 67 - 70
Accepted: Mar 25, 2022
DOI: https://doi.org/10.2478/rojost-2021-0012
Keywords
© 2021 Costache Mihai-Aurel et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Benign bone tumors represent an important chapter in the pathology of the musculoskeletal system, most commonly affecting young people under the age of 30. The most common benign bone tumors diagnosed in orthopedic surgery are: osteochondroma, osteoid osteoma, osteoblastoma, giant cell tumor, bone aneurysmal cyst, and fibrous dysplasia. An important feature is the lack of secondary determinations.
Depending on the type and the location of the benign bone tumors, treatment can be non-surgical or surgical.
Patients included in the study were between 25 and 55 years old with an average age of 40.
In both cases, the radiological image remains the routine investigation in the periodic postoperative control.
The purpose of this study was to compare the surgical treatment (curettage-filling) with synthetic bone substitute, compared to autograft in patients with benign bone tumors.